Literature DB >> 8321327

Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors.

K Niiya1, K A Jacobson, S K Silvia, R A Olsson.   

Abstract

Experiments employing guinea pig heart Langendorff preparations compared the coronary vasoactivity of a functionalized congener of adenosine, 2-[(2-aminoethyl-aminocarbonylethyl)phenylethylamino]-5'-N-e thyl- carboxamidoadenosine, APEC, with the vasoactivity of the product of the reaction of APEC with 1,4-phenylene-diisothiocyanate, 4-isothiocyanatophenylaminothiocarbonyl-APEC (DITC-APEC). Previous experiments showed that whereas APEC binds reversibly to the A2A adenosine receptor of brain striatum, DITC-APEC binds irreversibly. APEC caused concentration-dependent coronary vasodilation that persisted unchanged when agonist administration continued for up to 165 min, but promptly faded when the agent was withdrawn. The unselective adenosine receptor antagonist 8-(4-sulfophenyl)theophyline (8-SPT) antagonized the vasoactivity of APEC. By contrast, DITC-APEC (0.125-1.0 nM) caused progressive, concentration-independent vasodilation that persisted unchanged for as long as 120 min after the agent was stopped and that was insensitive to antagonism by subsequently applied 8-SPT. However, perfusion of the heart with buffer containing 0.1 mM 8-SPT strongly antagonized the coronary vasodilatory action of DITC-APEC given subsequently. Such observations indicate that the covalent binding of DITC-APEC causes irreversible activation of the guinea pig coronary artery A2A adenosine receptor. Neither APEC nor DITC-APEC appeared to desensitize the coronary adenosine receptor during two or more hours of exposure to either agonist.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321327      PMCID: PMC3437322          DOI: 10.1007/BF00166745

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  26 in total

1.  [3H]2-phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain.

Authors:  L J Cornfield; S Hu; S D Hurt; M A Sills
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

2.  Chemical modification and irreversible inhibition of striatal A2a adenosine receptors.

Authors:  K A Jacobson; G L Stiles; X D Ji
Journal:  Mol Pharmacol       Date:  1992-07       Impact factor: 4.436

3.  (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists.

Authors:  J Shimada; F Suzuki; H Nonaka; A Ishii; S Ichikawa
Journal:  J Med Chem       Date:  1992-06-12       Impact factor: 7.446

4.  Cardiovascular actions of adenosines, but not adenosine receptors, differ in rat and guinea pig.

Authors:  M Ueeda; R D Thompson; W L Padgett; S Secunda; J W Daly; R A Olsson
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

5.  Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells.

Authors:  V Ramkumar; M E Olah; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1991-11       Impact factor: 4.436

6.  Prolonged in vitro exposure of rat brain slices to adenosine analogues: selective desensitization of adenosine A1 but not A2 receptors.

Authors:  M P Abbracchio; G Fogliatto; A M Paoletti; G E Rovati; F Cattabeni
Journal:  Eur J Pharmacol       Date:  1992-11-02       Impact factor: 4.432

7.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.

Authors:  Q Y Zhou; C Li; M E Olah; R A Johnson; G L Stiles; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.

Authors:  J E Francis; R L Webb; G R Ghai; A J Hutchison; M A Moskal; R deJesus; R Yokoyama; S L Rovinski; N Contardo; R Dotson
Journal:  J Med Chem       Date:  1991-08       Impact factor: 7.446

9.  Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A2 receptor agonists with potent antihypertensive effects.

Authors:  A Matsuda; M Shinozaki; T Yamaguchi; H Homma; R Nomoto; T Miyasaka; Y Watanabe; T Abiru
Journal:  J Med Chem       Date:  1992-01-24       Impact factor: 7.446

10.  A2-adenosine receptor stimulation increases macromolecule permeability of coronary endothelial cells.

Authors:  H Watanabe; W Kuhne; P Schwartz; H M Piper
Journal:  Am J Physiol       Date:  1992-04
View more
  13 in total

1.  Persistent activation by and receptor reserve for an irreversible A1-adenosine receptor agonist in DDT1 MF-2 cells and in guinea pig heart.

Authors:  J Zhang; L Belardinelli; K A Jacobson; D H Otero; S P Baker
Journal:  Mol Pharmacol       Date:  1997-09       Impact factor: 4.436

2.  Functionalized congeners of 1,4-dihydropyridines as antagonist molecular probes for A3 adenosine receptors.

Authors:  A H Li; L Chang; X d Ji; N Melman; K A Jacobson
Journal:  Bioconjug Chem       Date:  1999 Jul-Aug       Impact factor: 4.774

3.  8-(3-Isothiocyanatostyryl)caffeine Is a Selective, Irreversible Inhibitor of Striatal A(2)-Adenosine Receptors.

Authors:  Xiao-Duo Ji; Carola Gallo-Rodriguez; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  2004-10-05       Impact factor: 4.360

Review 4.  Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.

Authors:  Kenneth A Jacobson
Journal:  J Med Chem       Date:  2013-05-09       Impact factor: 7.446

Review 5.  Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).

Authors:  Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2009-04-30       Impact factor: 4.774

6.  Structure-Based Design of Reactive Nucleosides for Site-Specific Modification of the A2A Adenosine Receptor.

Authors:  Steven M Moss; P Suresh Jayasekara; Silvia Paoletta; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  ACS Med Chem Lett       Date:  2014-07-11       Impact factor: 4.345

7.  A selective agonist affinity label for A3 adenosine receptors.

Authors:  X D Ji; C Gallo-Rodriguez; K A Jacobson
Journal:  Biochem Biophys Res Commun       Date:  1994-08-30       Impact factor: 3.575

8.  Structure-Activity Relationships of the Sustained Effects of Adenosine A2A Receptor Agonists Driven by Slow Dissociation Kinetics.

Authors:  J Daniel Hothersall; Dong Guo; Sunil Sarda; Robert J Sheppard; Hongming Chen; Wesley Keur; Michael J Waring; Adriaan P IJzerman; Stephen J Hill; Ian L Dale; Philip B Rawlins
Journal:  Mol Pharmacol       Date:  2016-11-01       Impact factor: 4.436

9.  Application of the functionalized congener approach to dendrimer-based signaling agents acting through A(2A) adenosine receptors.

Authors:  Yoonkyung Kim; Athena M Klutz; Béatrice Hechler; Zhan-Guo Gao; Christian Gachet; Kenneth A Jacobson
Journal:  Purinergic Signal       Date:  2008-07-04       Impact factor: 3.765

10.  Enhanced A3 adenosine receptor selectivity of multivalent nucleoside-dendrimer conjugates.

Authors:  Athena M Klutz; Zhan-Guo Gao; John Lloyd; Asher Shainberg; Kenneth A Jacobson
Journal:  J Nanobiotechnology       Date:  2008-10-23       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.